CriticalAntiepileptics. Barbiturates×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
The liver clears voriconazole through the enzymes CYP2C19, CYP2C9 and CYP3A4, and drugs that speed up these enzymes lower its blood levels (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Phenobarbital strongly induces liver cytochrome P450 enzymes, glucuronosyltransferases and the transporter P-glycoprotein, so many drugs are cleared faster and work less well (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The combination has not been studied. According to the voriconazole SmPC and label, long-acting barbiturates are likely to lower voriconazole levels markedly, and the antifungal effect may be lost (voriconazole SmPC, EMA, and voriconazole label, US Food and Drug Administration, FDA). In the other direction, voriconazole inhibits CYP2C9 and CYP2C19 (voriconazole SmPC, EMA). These enzymes clear phenobarbital, and the label of the neonatal phenobarbital product states that their inhibitors may raise phenobarbital levels (phenobarbital label, FDA).
Symptoms
The drop in voriconazole levels itself causes no symptoms: the only sign is that the fungal infection does not improve or comes back on the usual dose. Voriconazole is used for invasive aspergillosis, candidaemia and other serious fungal infections, mainly when the infection is progressing and may be life-threatening, and for prevention after haematopoietic stem cell transplant (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Loss of its effect is therefore dangerous. If voriconazole raises phenobarbital levels, the label of the neonatal phenobarbital product warns that over-sedation and prolongation of the corrected QT interval (QTc) may follow (phenobarbital label, US Food and Drug Administration, FDA). QTc prolongation and rare cases of torsade de pointes have been reported with voriconazole itself (voriconazole SmPC, EMA).
Management
The combination is contraindicated. Voriconazole must not be given with long-acting barbiturates, and its labels name phenobarbital directly (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, and voriconazole label, US Food and Drug Administration, FDA). The phenobarbital SmPC does not mention voriconazole, but warns that its strong enzyme induction can cause clinically relevant interactions with many drug groups (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Monitor the drugs on its list, including the antifungal itraconazole, and adjust their doses as required during phenobarbital treatment and after it stops (phenobarbital SmPC, AEMPS). Do not stop phenobarbital abruptly; taper the dose. In a person with dependence, abrupt withdrawal after long use can cause delirium, seizures and possibly death (phenobarbital SmPC, AEMPS). Check potassium, magnesium and calcium before and during voriconazole treatment and correct them if needed (voriconazole SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- AEMPS: Ficha técnica: Voriconazol (nº registro 80105), sección 4.3 (2026)– AEMPS, CIMA, nº registro 80105, revisión 04/2026, sección 4.3
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Fenobarbital (nº registro 35052), sección 4.5 (2025)– AEMPS, CIMA, nº registro 35052 (Luminal 100 mg comprimidos), revisión 07/2025 (texto de marzo de 2025), secciones 4.2, 4.4 y 4.5
- FDA: SEZABY (phenobarbital sodium) prescribing information (2025)– FDA, DailyMed setid 8c7d0402-4977-4c25-bc4b-11db91339e9a (Sun Pharmaceutical Industries), versión 7 de 12/2025 (texto revisado 02/2023), secciones 5.10, 7.1, 7.3 y 12.3